More threads by Retired


Abilify (aripiprazole)

U.S. Food and Drug Administration approves new indication : November 16, 2007

Treatment for: Add-On Treatment of Major Depressive Disorder

Abilify is a dopamine partial agonist atypical antipsychotic drug. Abilify was first approved in November 2002 and is used for the treatment of schizophrenia, bipolar disorder and agitation associated with schizophrenia or bipolar mania. Abilify is now also indicated as an adjunctive, or add-on, treatment to antidepressant therapy (ADT) in adults with major depressive disorder (MDD).

"The approval of this new add-on treatment option is critical for adults suffering from depression who cannot find sufficient relief for their symptoms with antidepressants alone," said Madhukar Trivedi, M.D., Professor and Chief- Division of Mood Disorders, University of Texas Southwestern Medical School, Dallas, Texas. "Now physicians have a proven new option they can add to their patients' antidepressant treatments to help them feel better and relieve unresolved depressive symptoms."

Complete News Release

At this time, it is not clear if the manufacturer has made submissions for the same indication in Canada.
Replying is not possible. This forum is only available as an archive.